Oculis Holding AG (NASDAQ:OCS) Short Interest Update

Oculis Holding AG (NASDAQ:OCS) was the target of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 29,100 shares, a growth of 127.3% from the January 31st total of 12,800 shares. Based on an average trading volume of 70,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 0.1% of the company’s stock are sold short.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Chardan Capital restated a “buy” rating and set a $28.00 price objective on shares of Oculis in a research note on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Oculis in a research report on Monday, January 6th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $28.80.

Institutional Investors Weigh In On Oculis

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new stake in Oculis in the 4th quarter valued at $389,000. Bank of America Corp DE boosted its holdings in Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock valued at $493,000 after purchasing an additional 10,667 shares during the last quarter. Bellevue Group AG purchased a new stake in shares of Oculis in the 4th quarter valued at approximately $170,000. XTX Topco Ltd acquired a new stake in shares of Oculis during the 4th quarter worth approximately $225,000. Finally, Geode Capital Management LLC raised its position in shares of Oculis by 12.0% during the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after buying an additional 1,800 shares during the period. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Stock Performance

Shares of OCS stock traded down $0.10 during trading hours on Friday, hitting $19.58. The company’s stock had a trading volume of 38,424 shares, compared to its average volume of 93,908. The stock has a market cap of $793.07 million, a PE ratio of -10.15 and a beta of -0.24. The company has a 50 day moving average of $20.53 and a 200 day moving average of $16.41. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. Oculis has a 12-month low of $10.55 and a 12-month high of $23.08.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.